Lectin-based immunoassay for aberrant IgG glycosylation as the biomarker for Crohn's disease

Inflammatory Bowel Diseases

Volumn 19, Issue 2, 2013, Pages 321-331

  Shinzaki, Shinichiro ^a   Kuroki, Eri ^a   Iijima, Hideki ^a   Tatsunaka, Norika ^a   Ishii, Mayuko ^a   Fujii, Hironobu ^a   Kamada, Yoshihiro ^a   Kobayashi, Taku ^b   Shibukawa, Narihiro ^a   Inoue, Takahiro ^a   Tsujii, Masahiko ^a   Takeishi, Shunsaku ^c   Mizushima, Tsunekazu ^d   Ogata, Atsushi ^d   Naka, Tetsuji ^e   Plevy, Scott E ^b   Takehara, Tetsuo ^a   Miyoshi, Eiji ^a  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^c GP BioScience Ltd   (Japan)

^d OSAKA UNIVERSITY MEDICAL SCHOOL   (Japan)

^e NATIONAL INSTITUTE OF BIOMEDICAL INNOVATION   (Japan)

Author keywords

Biomarker; Crohn's disease; IgG; Inflammatory bowel disease; Oligosaccharides

Indexed keywords

AGGLUTININ; IMMUNOGLOBULIN G; OLIGOSACCHARIDE;

ADULT; AGARICUS BISPORUS; ARTICLE; BINDING AFFINITY; CROHN DISEASE; DISEASE ACTIVITY; DISEASE CONTROL; ENZYME IMMUNOASSAY; FEMALE; GLYCOSYLATION; GRIFFONIA; GRIFFONIA SIMPLICIFOLIA; HUMAN; IMMUNOADSORBENT; MAJOR CLINICAL STUDY; MALE; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN BLOOD LEVEL; PROTEIN INTERACTION; PROTEIN MICROARRAY;

ADOLESCENT; ADULT; AGED; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CROHN DISEASE; ELECTROPHORESIS, POLYACRYLAMIDE GEL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; IMMUNOGLOBULIN G; JAPAN; LECTINS; MALE; MIDDLE AGED; PLANT LECTINS; PREDICTIVE VALUE OF TESTS; PROTEIN ARRAY ANALYSIS; ROC CURVE; UNITED STATES; YOUNG ADULT;

EID: 84876396017     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1097/MIB.0b013e318280eade     Document Type: Article

References (38)

1. Behm BW, Bickston SJ. Tumor necrosis factor-alpha antibody for maintenance of remission in Crohn's disease. Cochrane Database Syst Rev. 2008:CD006893.
2. Prefontaine E, Macdonald JK, Sutherland LR. Azathioprine or 6-mercaptopurine for induction of remission in Crohn's disease. Cochrane Database Syst Rev. 2010:CD000545.
3. Cannom RR, Kaiser AM, Ault GT, et al. Inflammatory bowel disease in the United States from 1998 to 2005: has infliximab affected surgical rates? Am Surg. 2009;75:976-980.
4. Main J, McKenzie H, Yeaman GR, et al. Antibody to Saccharomyces cerevisiae (bakers' yeast) in Crohn's disease. BMJ. 1988;297:1105-1106.
5. Quinton JF, Sendid B, Reumaux D, et al. Anti-Saccharomyces cerevisiae mannan antibodies combined with antineutrophil cytoplasmic autoantibodies in inflammatory bowel disease: prevalence and diagnostic role. Gut. 1998;42:788-791.
6. Benor S, Russell GH, Silver M, et al. Shortcomings of the inflammatory bowel disease Serology 7 panel. Pediatrics. 2010;125:1230-1236.
7. Shinzaki S, Iijima H, Nakagawa T, et al. IgG oligosaccharide alterations are a novel diagnostic marker for disease activity and the clinical course of inflammatory bowel disease. Am J Gastroenterol. 2008;103:1173-1181.
8. Nakajima S, Iijima H, Shinzaki S, et al. Functional analysis of agalactosyl IgG in inflammatory bowel disease patients. Inflamm Bowel Dis. 2011;17:927-936.
9. Matsumoto H, Shinzaki S, Narisada M, et al. Clinical application of a lectin-antibody ELISA to measure fucosylated haptoglobin in sera of patients with pancreatic cancer. Clin Chem Lab Med. 2010;48:505-512.
10. Hirabayashi J. Oligosaccharide microarrays for glycomics. Trends Biotechnol. 2003;21:141-143; discussion 143.
11. Lennard-Jones J. Classification of inflammatory bowel disease. Scand J Gastroenterol Suppl. 1989;170:2-6; discussion 16-19.
12. Podolsky D. Inflammatory bowel disease (1). N Engl J Med. 1991;325: 928-937.
13. Podolsky D. Inflammatory bowel disease (2). N Engl J Med. 1991;325: 1008-1016.
14. Satsangi J, Silverberg MS, Vermeire S, et al. The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications. Gut. 2006;55:749-753.
15. Best W, Becktel J, Singleton J, et al. Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study. Gastroenterology. 1976;70:439-444.
16. Rachmilewitz D. Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomised trial. BMJ. 1989;298:82-86.
17. Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet. 2002;359: 1541-1549.
18. Kuno A, Uchiyama N, Koseki-Kuno S, et al. Evanescent-field fluorescence- assisted lectin microarray: a new strategy for glycan profiling. Nat Methods. 2005;2:851-856.
19. Yamada Y, Hosoda T, Yoshizawa M, et al. Development and evaluation of the lectin-enzyme immune assay kit for detection of anti-agalactosyl IgG antibodies. Clin Rep. 1997;31:81-101.
20. Beck JR, Shultz EK. The use of relative operating characteristic (ROC) curves in test performance evaluation. Arch Pathol Lab Med. 1986;110: 13-20.
21. Zweig MH, Campbell G. Receiver-operating characteristic (ROC) plots: a fundamental evaluation tool in clinical medicine. Clin Chem. 1993;39: 561-577.
22. Nakamura-Tsuruta S, Kominami J, Kamei M, et al. Comparative analysis by frontal affinity chromatography of oligosaccharide specificity of GlcNAc-binding lectins, Griffonia simplicifolia lectin-II (GSL-II) and Boletopsis leucomelas lectin (BLL). J Biochem. 2006;140:285-291.
23. Nakamura-Tsuruta S, Kominami J, Kuno A, et al. Evidence that Agaricus bisporus agglutinin (ABA) has dual sugar-binding specificity. Biochem Biophys Res Commun. 2006;347:215-220.
24. Kornfeld R, Ferris C. Interaction of immunoglobulin glycopeptides with concanavalin A. J Biol Chem. 1975;250:2614-2619.
25. Presant CA, Kornfeld S. Characterization of the cell surface receptor for the Agaricus bisporus hemagglutinin. J Biol Chem. 1972;247:6937-6945.
26. Chatterjee BP, Ahmed H, Uhlenbruck G, et al. Jackfruit (Artocarpus integrifolia) and the Agaricus mushroom lectin fit also to the so-called peanut receptor. Behring Inst Mitt. 1985;148-158.
27. Paulson JC, Blixt O, Collins BE. Sweet spots in functional glycomics. Nat Chem Biol. 2006;2:238-248.
28. Huhn C, Selman MH, Ruhaak LR, et al. IgG glycosylation analysis. Proteomics. 2009;9:882-913.
29. Magro F, Portela F, Lago P, et al. Crohn's disease in a southern European country: Montreal classification and clinical activity. Inflamm Bowel Dis. 2009;15:1343-1350.
30. Hampe J, Cuthbert A, Croucher PJ, et al. Association between insertion mutation in NOD2 gene and Crohn's disease in German and British populations. Lancet. 2001;357:1925-1928.
31. Hugot JP, Chamaillard M, Zouali H, et al. Association of NOD2 leucinerich repeat variants with susceptibility to Crohn's disease. Nature. 2001; 411:599-603.
32. Ogura Y, Bonen DK, Inohara N, et al. A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease. Nature. 2001;411:603-606.
33. Yamazaki K, Takazoe M, Tanaka T, et al. Absence of mutation in the NOD2/CARD15 gene among 483 Japanese patients with Crohn's disease. J Hum Genet. 2002;47:469-472.
34. Parekh RB, Dwek RA, Sutton BJ, et al. Association of rheumatoid arthritis and primary osteoarthritis with changes in the glycosylation pattern of total serum IgG. Nature. 1985;316: 452-457.
35. Tomana M, Schrohenloher RE, Koopman WJ, et al. Abnormal glycosylation of serum IgG from patients with chronic inflammatory diseases. Arthritis Rheum. 1988;31:333-338.
36. Parekh R, Isenberg D, Rook G, et al. A comparative analysis of diseaseassociated changes in the galactosylation of serum IgG. J Autoimmun. 1989;2:101-114.
37. Das H, Atsumi T, Fukushima Y, et al. Diagnostic value of antiagalactosyl IgG antibodies in rheumatoid arthritis. Clin Rheumatol. 2004;23: 218-222.
38. Malhotra R, Wormald MR, Rudd PM, et al. Glycosylation changes of IgG associated with rheumatoid arthritis can activate complement via the mannose- binding protein. Nat Med. 1995;1:237-243.